24/7 Market News Snapshot 11 June, 2025 – Kazia Therapeutics Limited American Depositary Shares (NASDAQ:KZIA)

June 11, 2025

DENVER, Colo., 11 June, 2025 (www.247marketnews.com) – (NASDAQ:KZIA) are discussed in this article.
Kazia Therapeutics Limited (NASDAQ:KZIA) is currently experiencing a notable surge in investor interest, with shares trading at $7.55, reflecting a remarkable increase of 43.66% from the prior close of $5.25. The stock has shown strong momentum with a trading volume of 2.54 million shares, suggesting heightened enthusiasm likely spurred by recent developments surrounding the company.

Central to this interest is the publication of groundbreaking preclinical research that showcases the potential of Kazia’s lead therapeutic candidate, paxalisib, in the fight against triple-negative breast cancer (TNBC), an aggressive and treatment-resistant cancer subtype. The study, conducted by Professor Sudha Rao at a prestigious medical research institute and published in the journal Molecular Cancer Therapeutics, highlights paxalisib’s ability to reprogram the tumor microenvironment. This reprogramming enhances immune response, significantly increasing T cell infiltration and activation, thus showing promise as a transformative treatment option.

The research further emphasizes the synergistic potential of paxalisib when used in conjunction with immune checkpoint inhibitors, particularly KEYTRUDA® (pembrolizumab). Early findings indicate considerable antitumor activity, yielding robust tumor regression and improved survival rates in preclinical models. Dr. John Friend, CEO of Kazia, expressed optimism regarding these findings, which lay the groundwork for the company’s newly launched Phase 1b clinical trial evaluating paxalisib alongside checkpoint inhibitors in advanced breast cancer.

The initiation of this clinical trial marks a critical milestone in translating the research’s promising results into practical treatments for patients. As Kazia continues to explore options to expand paxalisib’s therapeutic use beyond brain cancers, its innovative approach stands poised to redefine treatment pathways for patients encountering some of the most formidable cancer challenges.

Related news for (KZIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.